Immune Protective Health Formulation – AstaReal® Positioning

Claim	Reference	Study Design	Participants	Dose	Results	Page #
Supports healthy immune response	Park J.S. et al. Nutr Metab (Lond). 2010;7:18.	DBPC	42 healthy subjects	0, 2, 8 mg/day	8 mg/day: higher mitogen induced lymphocyte proliferation response compared to placebo with phytohemagglutinin, Concanavalin A, and pokeweek mitogens (p<0.05). 8 mg/day: 17% increase in NK cytotoxic activity vs. placebo after 8 weeks (p<0.05) 2 mg/day: ~6% increase in skin reaction area at 72hr in delayed-type hypersensitivity tuberculin test vs. placebo (p<0.05)	Pg 4, Fig 2 Pg 5, Table 2 Pg 5, Fig 3
Supports healthy immune response	Baralic et al. Evidence-Based Complementary and Alt. Med. 2015 (4): 1-9 (2015).	DBPC	40 healthy subjects	0, 4 mg/day	4 mg/day: increased slgA concentration after 90 days of supplementation vs. baseline (p<0.05) 4 mg/day: increased slgA secretion rate after 90 days of supplementation vs. baseline (p<0.05)	Pg 5, Fig 1
Supports healthy immune response	Hongo et al. 2016. J Clin Ther Med. 32(7)577-91.	DBPC	39 healthy subjects	0, 12 mg/day	12 mg/day: Salivary SlgA concentration stable over the course of 8 weeks in spite of mental/physical stress loads. In contrast, placebo group had decrease in salivary slgA concentration after 8 weeks vs. baseline (p<0.05).	Pg 19, Fig 5
Supports healthy	Park J.S. et al. <i>Nutr Metab</i>	DBPC	42 healthy subjects	0, 2, 8 mg/day	8 mg/day: IFN-y levels greater in 8mg group (9.55	Pg 6, Table 3

inflammation	(Lond).				pg/mL) vs. placebo	
response	2010;7:18.				(4.68 pg/mL) after 8 weeks (p<0.05)	
\\ \landslandslandslandslandslandslandslands					8 mg/day: IL-6	
(\wedge')					levels greater in	
					8mg group (25.2	
					pg/mL) vs. placebo	
					(13.6 pg/mL) after	
					8 weeks (p<0.05)	Pg 6,
					2 mg/day: CRP	Fig 4
					levels lower after 8 weeks compared	
					to placebo	
					(p<0.05)	
Supports	Baralic et al.	DBPC	40 healthy	0, 4	4 mg/day: CRP	
healthy	Evidence-Based		subjects	mg/day	levels did not	
inflammation	Complementary				increase after 90	
response	and Alt. Med.				days of training	
. ^	2015 (4): 1-9				following 2 hour bout of exercise	
(14)	(2015).				compared to	
					baseline. In	
					contrast, 57%	
					increase in CRP	
					was observed in	
					placebo group	
					after 90 day	
					training following 2 hr exercise session	
					(p=0.05).	
Antioxidant	Park J.S. et	DBPC	42 healthy	0, 2, 8	2 mg/day:	Pg 7,
,••	al. Nutr Metab		subjects	mg/day	Concentrations of	Fig 5
$\{(\bigcirc)\}$	(Lond).				plasma 8-hydroxy-	
	2010;7:18.				2'-deoxyguanosine	
					reduced after 4	
					weeks and 8 weeks	
					compared to placebo (p<0.05)	
					8 mg/day:	Pg 7,
					Concentrations of	Fig 5
					plasma 8-hydroxy-	
					2'-deoxyguanosine	
					reduced after 4	
					weeks and 8 weeks	
					compared to	
					placebo (p<0.05)	
			<u> </u>			

Antioxidant	Baralic et al. Evidence-Based Complementary and Alt. Med. 2015 (4): 1-9 (2015).	DBPC	40 healthy subjects	0, 4 mg/day	4 mg/day: Prooxidant Antioxidant Balance (PAB) decreased after 90 days vs baseline (p<0.05) attributed to combined training and supplementation effect	Pg 5, Table 3
Antioxidant	Hashimoto H. et al. Rinsho Ganka (Jpn J Clin Ophthalmol) 65(4): 465-470, 2011.	uncontrolled	35 cataract patients	0, 6 mg/day	6 mg/day: AstaReal® Astaxanthin reduces total hydroperoxides (hydrogen peroxides, lipid peroxides, and peroxides of protein in aqueous humor; p<0.05)	
Antioxidant	Iwabayashi M. et al. Anti-Aging Medicine 6(4): 15- 21, 2009.	Uncontrolled	35 healthy subjects	12 mg/day	AstaReal® Astaxanthin increases blood biological antioxidant potential (BAP; +4.6%, p<0.05)	
Antioxidant	Karppi, J. et al. Int. J. Vitam. Nutr. Res. 77(1): 3-11, 2007.	DBPC	39 healthy subjects	0, 8 mg/day	8 mg/day: AstaReal® Astaxanthin decreases oxidation of fatty acids in healthy men (p<0.05)	
Antioxidant	Hashimoto H. et al. Atarashii Ganka (Journal of the Eye) 26 (2):229-234, 2009. and Hashimoto, H. et al. J. Clin. Biochem. Nutr. 53(1): 1-7, 2013.	Uncontrolled	35 cataract patients	6 mg/day	6 mg/day: AstaReal® Astaxanthin increases superoxide scavenging activity (p< 0.05)	
Antioxidant	Yamada T. et al. J. Clin. Biochem.	Uncontrolled	6 healthy subjects	12 mg/day	12 mg/day: reduces total	

	Nutr., 47: 130–137, 2010.		and 6 Sjoegren's syndrome subjects		salivary HEL oxidation marker in SS patients (p<0.05)
Antioxidant	Baralic I. et al. Phytother. Res. 27: 1536–1542, 2013.	DBPC	40 healthy subjects	0, 4 mg/day	4 mg/day: protection of thiol groups against oxidative modification (increase in -SH groups, p<0.05; improved PON1 activity towards paraoxon and diazoxon, p<0.05 and p<0.01, respectively)
Antioxidant	Fujino, H. et al. Medicine and science in sports and exercise. 48. 129. Board #290 June 1, 2016.	DBPC	29 healthy subjects	0, 24 mg/day	24 mg/day: reduced derivatives of reactive oxygen metabolites (d- ROM; p<0.01)

Immune Function notes:

- B Cell a lymphocyte not processed by the thymus gland, and responsible for producing antibodies.
- T Cell a lymphocyte of a type produced or processed by the thymus gland and actively participating in the immune response.
- T cell-dependent (phytohemagglutinin, concanavalin A) and B cell-dependent (pokeweed mitogen) mitogens
- SIgA is an antibody produced by B cells that inhibits the proliferation of pathogens on the mucosa of the oral cavity, airway, intestines, and other organs.

Healthy Inflammation Response

Antioxidant Support